Clinical Experience With Polyclonal IgM-Enriched Immunoglobulins in a Group of Patients Affected by Sepsis After Cardiac Surgery

The protective effects of IgM-enriched immunoglobulin and erythropoietin on the lung and small intestine tissues of rats with induced sepsis: Biochemical and histopathological evaluation

“…IgM-enriched IVIG contains Ig M, Ig A, and Ig G and it was shown that IgM-enriched IVIG (250 mg/kg) is more efficient than standard IgG IVIG in terms of toxin neutralization and bacterial agglutination in cases with superantigen-mediated sepsis (Darenberg et al, 2004;Norrby-Teglund et al, 2006). In a retrospective study (Buda et al, 2005) analyzing the data of 66 patients diagnosed with sepsis in the cardiovascular intensive care unit; 22 patients received IgM-enriched immunoglobulins in addition to the conventional therapy had a higher survival rate compared with the other 44 patients who received only conventional therapy. In a study (Yavuz et al, 2012), adding Ig M-enriched IVIG therapy to standard therapy improved general clinical conditions and significantly reduced overall mortality rate in patients with sepsis-induced multiple organ dysfunction syndrome.…”

Intravenous polyclonal IgM‐enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis

“…Combination of the 10 studies revealed a significant reduction of mortality in the IVIG group compared with controls ( P < 0.00001 determined by meta‐analysis using a fixed‐effect model). This significant benefit from the IVIG treatment was seen even when the nonrandomized studies [58, 59] were excluded from the analysis (RR 0.35; 95% CI 0.23–0.54; U = 22.96, P < 0.00001).…”

“…These included four studies in neonates or paediatric patients, and six with adult or adolescent patients. Three studies enrolled patients with severe sepsis or septic shock [9, 56, 57] and in one study [58] severe sepsis cases were evaluated in a subgroup analysis. All studies showed reduced mortality rates amongst cases receiving IVIG compared with controls, but only four [9, 59–61] reached significant differences (Tables 1 and 2).…”

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.

“…Titles of the 215 references were scanned for relevance, based on the inclusion criteria, and this identified 48 references as potentially relevant. Abstracts of the 48 references (available from the authors on request) were scanned for relevance, again based on the inclusion criteria, and this identified 12 references [42][43][44][45]53,56,59,[60][61][62][63][64] as potentially relevant. Full-text copy was obtained for each of the 12 references and, of these, six [42][43][44][45]53,56 were already identified from the six previous systematic reviews.…”

“…Full-text copy was obtained for each of the 12 references and, of these, six [42][43][44][45]53,56 were already identified from the six previous systematic reviews. Of the remaining six, 59-64 one 60 was a duplicate reference and five 59,[61][62][63][64] failed to meet the inclusion criteria for our current review ( Table 5). In summary, no new studies were identified for inclusion to update the existing systematic review.…”